In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Naveed Sattar
Speaker
Naveed Sattar
Naveed Sattar Naveed Sattar

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

Speciality : Risk Factors and Prevention

Professor Naveed Sattar is one of the world’s top diabetes/metabolic medicine experts. Based in the Institute of Cardiovascular & Medical Sciences at the University of Glasgow, he is a Clarivate Analytics Global Highly Cited Researcher for 2019, one of ten Glasgow researchers recognised as being in the top 1% for citations in their academic field. His research focuses on the prevention and management of diabetes, obesity and CVD. He has published over 950 papers, participated in multiple guidelines and clinical trials, as well as been the recipient of multiple award lectures. His main contributions have helped define CVD risks in diabetes including the relevance of age of onset, ethnicity, specific drugs, and sex. He has also helped define CVD risks in autoimmune conditions and has helped improve knowledge on general CVD risk factors including lipids, role of obesity, and alcohol. He also has a track record of work on novel biomarkers. He is involved in several ongoing trials.

30 presentations from this speaker

Connecting with the speakers - Questions and answers

Event : ESC Congress 2019

  • Session : Improving cardiovascular risk in patients with obesity
  • Speaker : L Ryden (Stockholm,SE), N Sattar (Glasgow,GB), E Bohula (Boston,US)
  • Sponsored by Novo Nordisk A/S

Does weight loss affect cardiovascular risk?

Event : ESC Congress 2019

  • Session : Improving cardiovascular risk in patients with obesity
  • Speaker : N Sattar (Glasgow,GB)
  • Sponsored by Novo Nordisk A/S

Epidemiology and registry-based research in Circulation.

Event : ESC Congress 2019

  • Session : The new Circulation: expanding frontiers
  • Speaker : N Sattar (Glasgow,GB)
  • Organised with the Circulation Journal

Integrating SGLT2 inhibitors in diabetes treatment: a guide for cardiologists

Event : ESC Congress 2019

  • Session : New frontiers: SGLT2 inhibitors in cardiorenal disease
  • Speaker : N Sattar (Glasgow,GB)

Lifestyle interventions: what works and why aren’t we using it?

Event : ESC Congress 2019

  • Session : Obesity care in people with cardiovascular disease: a neglected front? (Accredited by EACCME)
  • Speaker : N Sattar (Glasgow,GB)
  • Organised by International Medical Press, supported by an educational grant from Novo Nordisk A/S

New anti-diabetes medications: what the cardiologist needs to know.

Event : ESC Congress 2019

  • Session : Preventive cardiology: Essential Update Part 2
  • Speaker : N Sattar (Glasgow,GB)

Obesity care: new perspectives in the clinic

Event : ESC Congress 2019

  • Session : Obesity care in people with cardiovascular disease: a neglected front? (Accredited by EACCME)
  • Speaker : R Batterham (London,GB), N Sattar (Glasgow,GB), D McGuire (Dallas,US)
  • Organised by International Medical Press, supported by an educational grant from Novo Nordisk A/S

The diabetes challenge for cardiologists: the key things to understand

Event : ESC Congress 2019

  • Session : Transforming diabetes management in cardiology: impact of novel therapies
  • Speaker : N Sattar (Glasgow,GB)
  • Organised by PACE-CME, supported with an educational grant provided by Novo Nordisk

The magic of low-calorie diet.

Event : ESC Congress 2019

  • Session : The challenge of obesity
  • Speaker : N Sattar (Glasgow,GB)

Advancing the standard of care in patients with type 2 diabetes and established cardiovascular disease: how can we improve patient outcomes? .

Event : ESC Congress 2018

  • Session : Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice
  • Speaker : N Marx (Aachen,DE), D McGuire (Dallas,US), JA Udell (Toronto,CA), S Verma (Toronto,CA), N Sattar (Glasgow,GB)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Applying evidence in practice: appropriate use of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in the cardiology clinic.

Event : ESC Congress 2018

  • Session : Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice
  • Speaker : JA Udell (Toronto,CA), N Sattar (Glasgow,GB)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Brief update on SGLT2 inhibition in heart failure and diabetes.

Event : Heart Failure 2018

  • Session : Management of heart failure in patients with diabetes: implications from recent trials
  • Speaker : N Sattar (Glasgow,GB)
  • Sponsored by Physicians Academy for Cardiovascular Education

Diabetes treatment: what the cardiologist needs to know.

Event : ESC Congress 2018

  • Session : Preventive cardiology: review, update, and State of the Art in 2018 - Part 2
  • Speaker : N Sattar (Glasgow,GB)

Heart failure as a serious but preventable complication of T2DM (Type 2 Diabetes Mellitus) – metabolic physician perspective.

Event : Heart Failure 2018

  • Session : Biomarker targeted approach in preventing heart failure among patients with diabetes
  • Speaker : N Sattar (Glasgow,GB)
  • Sponsored by Roche

Panel discussion and close - Optimising cardiovascular outcomes with PCSK9 inhibitors: start now before a potential next MI or stroke!

Event : ESC Congress 2018

  • Session : Optimising cardiovascular outcomes with PCSK9 inhibitors: start now before a potential next MI or stroke!
  • Speaker : U Laufs (Leipzig,DE), GM De Ferrari (Pavia,IT), N Sattar (Glasgow,GB), RP Giugliano (Boston,US)
  • Sponsored by Amgen Europe GmbH

Treating cardiovascular patients at risk: cases in action

Event : ESC Congress 2018

  • Session : Optimising cardiovascular outcomes with PCSK9 inhibitors: start now before a potential next MI or stroke!
  • Speaker : GM De Ferrari (Pavia,IT), U Laufs (Leipzig,DE), N Sattar (Glasgow,GB)
  • Sponsored by Amgen Europe GmbH

Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes.

Event : Heart Failure 2018

  • Session : Contemporary management of a patient with heart failure and diabetes: implications from recent trials
  • Speaker : N Sattar (Glasgow,GB)
  • Sponsored by Physicians Academy for Cardiovascular Education

What are the clinical implications for management of heart failure patients with diabetes?

Event : Heart Failure 2018

  • Session : Management of heart failure in patients with diabetes: implications from recent trials
  • Speaker : A Voors (Groningen,NL), M Cowie (London,GB), N Sattar (Glasgow,GB), F Zannad (Vandoeuvre,FR)
  • Sponsored by Physicians Academy for Cardiovascular Education

Epidemiology and registry-based research in Circulation.

Event : ESC Congress 2017

  • Session : The new Circulation: expanding frontiers
  • Speaker : N Sattar (Glasgow,GB)
  • Joint with Circulation

Panel discussion; SGLT2 in clinical cardiology.

Event : ESC Congress 2017

  • Session : Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure (EBAC Accredited)
  • Speaker : S Anker (Berlin,DE), N Sattar (Glasgow,GB), J Deanfield (,GB), D Fitchett (Toronto,CA)
  • Organised by Physicians' Academy for Cardiovascular Education, supported with an educational grant by Boehringer Ingelheim/Lilly

SGLT2 inhibition in cardiology: what a cardiologist needs to know.

Event : ESC Congress 2017

  • Session : Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure (EBAC Accredited)
  • Speaker : N Sattar (Glasgow,GB)
  • Organised by Physicians' Academy for Cardiovascular Education, supported with an educational grant by Boehringer Ingelheim/Lilly

SGLT2 inhibition in cardiology: what a cardiologist needs to know.

Event : ESC Congress 2017

  • Session : Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure (EBAC Accredited)
  • Speaker : N Sattar (Glasgow,GB)
  • Organised by Physicians' Academy for Cardiovascular Education, supported with an educational grant by Boehringer Ingelheim/Lilly

Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit.

Event : Heart Failure 2016

  • Session : Diabetes & heart failure: evaluating novel strategies to address outcomes
  • Speaker : N Sattar (Glasgow,GB)
  • Organised by the Physicians Academy for Cardiovascular Education (PACE) Foundation / Course Director: Prof Adriaan A Voors / Supported by an unrestricted educational grant from Boehringer Ingelheim

Metformin will remain the first option in oral treatment of diabetes

Event : ESC Congress 2016

  • Session : Cardio-diabetology alliance - The myth busters
  • Speaker : N Sattar (Glasgow,GB)
  • Joint with the European Association for the Study of Diabetes

Panel discussion.

Event : Heart Failure 2016

  • Session : Diabetes & heart failure: evaluating novel strategies to address outcomes
  • Speaker : S Anker (Berlin,DE), A Voors (Groningen,NL), D Fitchett (Toronto,CA), N Sattar (Glasgow,GB)
  • Organised by the Physicians Academy for Cardiovascular Education (PACE) Foundation / Course Director: Prof Adriaan A Voors / Supported by an unrestricted educational grant from Boehringer Ingelheim

Remaining cardiovascular risk: going beyond LDL-C.

Event : ESC Congress 2015

  • Session : Challenge the experts: best practice and future perspectives for residual risk management
  • Speaker : N Sattar (Glasgow,GB)
  • Sponsored by Lilly

State of the Art in reducing cardiovascular risk in diabetes.

Event : ESC Congress 2015

  • Session : Reducing cardiovascular risk in diabetes: one size does not fit all
  • Speaker : N Sattar (Glasgow,GB)

Glucose-lowering and cardiovascular disease: placing recent trials into context.

Event : ESC Congress 2014

  • Session : Hot topics in diabetes and cardiovascular disease
  • Speaker : N Sattar (Glasgow,GB)

Cardiovascular disease risk across the dysglycaemia spectrum: new paradigms at play.

Event : ESC Congress 2013

  • Session : Cardiovascular disease and diabetes interactions
  • Speaker : N Sattar (Glasgow,GB)

New ways to screen for diabetes and pre-diabetes?

Event : ESC Congress 2013

  • Session : Cardiovascular disease and diabetes interactions
  • Speaker : N Sattar (Glasgow,GB)

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are